Sanyou Bio & Biogeometry Partners to Make Antibody Drug Discovery Platform

Sanyou Bio and BioGeometry Team Up to Develop Innovative Antibody Drug Discovery Platform Driven by AIGC

Overview

BioGeometry and Sanyou Bio recently announced a strategic partnership agreement, signifying a significant collaboration in biotechnology.

BioGeometry

• BioGeometry, a digital biology pioneer, specializes in AI-driven protein design and research and development platforms. 
• Sanyou Bio, on the other hand, is a prominent biotechnology enterprise focusing on innovative biologic drug research and services.

Aim for Partnership

• The partnership aims to leverage both companies' expertise in generative AI technology and practical drug development experience to create a next-generation antibody drug discovery platform driven by AI. 
• They intend to collaborate with leading pharmaceutical companies to enhance the efficiency of new drug research and development.

Both Parties Post Agreement

• Sanyou Bio will integrate BioGeometry's proprietary generative AI antibody design platform, GeoBiologics, into its operations. 
• Both parties will invest to create an advanced Dry-Wet antibody R&D platform by merging BioGeometry's AI algorithm dry lab platform with Sanyou Bio's wet lab capabilities. 
• This platform will facilitate the development of more large molecule drug pipelines and nurture innovative projects.

Sanyou Bio has established a high-throughput R&D platform for innovative antibody drugs, boasting the world's largest antibody library and cutting-edge technical resources. Their platform integrates various molecule generation technologies and automated screening processes, focusing on generating molecules with superior characteristics.

Deep Learning Models by Biogeometry

• BioGeometry has developed geometric deep learning models that significantly reduce time and costs in antibody design. 
• Their GeoBiologics platform facilitates a closed-loop between dry and wet lab experiments, enhancing efficiency in discovering functional molecules.

Dr. Guojun Lang, CEO of Sanyou Bio, expressed confidence in BioGeometry's AI technology to transform their R&D platform, enhancing their competitiveness in new drug discovery.

CEO of Biogeometry on New Drug R&d

Dr. Jian Tang, CEO of BioGeometry, emphasized the joint creation of a cutting-edge AI-enabled antibody discovery platform with Sanyou Bio, aiming to revolutionize new drug R&D and accelerate advancements in antibody drug research.

Conclusion 

In summary, the strategic partnership between BioGeometry and Sanyou Bio marks a new era of collaboration in biotechnology, with a focus on innovation and efficiency in drug discovery and development.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!